CAS: 1415562-82-1; (R)-(1-(4-((3-Methyl-5-((Phenylsulfonyl)Methyl)Phenoxy)Methyl)Benzyl)Pyrrolidin-2-yl)Methanol

该化合物是酶磷酸三基酶(PI3K)的选择性抑制剂,具体针对PI3K伽马色素,该化合物主要研究其可能用于各种疾病,包括癌症和炎症的治疗用途.PF-543具有高度选择性,最大限度地减少非目标影响,使其成为研究环境中的宝贵工具.其行动机制涉及破坏PI3K信号路径,这对细胞生长,扩散和生存至关重要.在临床前的研究中,PF543在减少肿瘤生长和调控免疫反应方面显示出效力.此外,其药用基因特性,如吸收,分布,代谢和排泄,对于确定是否适合进一步发展为治疗剂至关重要.

结构式图片

上下游产品

3,5-Dimethylphenol 5-acetoxy-m-xylene 3-(bromomethyl)-5-methylphenyl acetate 4-(bromomethyl)benzaldehyde

合成工艺路线路线简述

    3-(溴甲基)-5-甲基苯基乙酸酯置于三乙酰氧基硼氢化钠,碳酸氢钠,Potassium Carbonate体系中,用 甲醇,水,1,2-二氯乙烷,乙腈 用作溶剂,化学反应 68.0H,反应生成(2R)-1-[[4-[[3-甲基-5-[(苯磺酰基)甲基]苯氧基]甲基]苯基]甲基]-2-吡咯烷甲醇
    参考文献:设计,合成和评估2-氨基噻唑衍生物作为鞘氨醇激酶抑制剂
    标题:设计,合成和评估2-氨基噻唑衍生物作为鞘氨醇激酶抑制剂
    摘要:鞘氨醇激酶(sphk1,Sphk2)是鞘氨醇-1-磷酸酯(s1P)的主要调节剂,鞘氨醇-1-磷酸酯是一种参与多种生理和病理生理功能的多效脂质介体.Sphk是新型抗癌和抗炎剂的靶标,这些抗癌剂和抗炎剂可促进细胞凋亡并调节自身免疫性疾病.本文中,我们描述了氨基噻唑类sphk抑制剂的设计,合成和评估.通过使用已知的ski-Ii支架进行一系列修饰来定义结构-活性关系,已经发现了有效的抑制剂.我们确定了n-(4-甲基噻唑-2-基)-(2,4'-Bithiazol)-2'-胺(24,St-1803 ; Ic 50 值:7.3μm(sphk1),6.5μm(sphk2))有望成为进一步体内研究和结构开发的有希望的候选者.
    Doi:10.1016/j.Bmc.2014.07.044

    海关参考信息

    专利信息


    专利号:US-11858953-B2
    优先权日:2018-04-04
    标 题:Compositions and methods for synthesis of phosphorylated molecules
    发明人:CHAPUT JOHN; LIAO JEN-YU; BALA SAIKAT
    权利人:UNIV CALIFORNIA
    摘要:The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

    专利号:WO-9102739-A1
    优先权日:1989-08-11
    标题:Synthesis of glycosides having predetermined stereochemistry
    发明人:DANISHEFSKY SAMUEL J
    权利人:UNIV YALE
    摘要:Methods of stereoselectively preparing a substituted 1,2-anhydrosugar wherein a substituted glycal is converted into a 1,2-anhydrosugar that is utilized to glycosylate a hydroxyl group containing glycal, are disclosed. Methods of preparing a saccharide multimer wherein a nucleophile is reacted with a substituted 1,2-anhydrosugar having a plurality of non-participating substituents, are disclosed. In addition, methods of preparing stereospecific halo-substituted saccharide multimers by haloglycosylation of a glycosyl donor substituted glycal and a glycosyl acceptor glycal derivative in the absence of water and in the presence of a halonium ion, are disclosed. Methods of preparing stereospecific particle-linked halo-substituted saccharide multimers, by haloglycosylation of a particle-linked nucleophilic hydroxyl group with a substituted glycal and a halonium ion, are also disclosed.

    专利号:US-10188136-B2
    优先权日:2016-02-16
    标题:Hydrophobin mimics: process for preparation thereof
    发明人:BRITTO Sandanaraj Selvaraj; REDDY Mullapudi Mohan; BHANDARI PAVANKUMAR JANARDHAN; RAO KASULADEVU JAGANNADHA
    权利人:INDIAN INSTITUTE OF SCIENCE EDUCATION AND RES
    摘要:The present invention discloses hydrophobin mimics of formula (I) comprising a protein head group, hydrophilic linker and hydrophobic tail and to a process for synthesis of library of hydrophobin mimics thereof. The hydrophobin mimics of the present invention self-assemble to form protein nanoparticles/nanocontainer either alone or in a specified chemical environment. The hydrophobin mimics (I) of the present invention find application in area of bio-nanotechnology.

    专利号:US-7125986-B2
    优先权日:1997-12-29
    标题:Penicillanic acid derivative compounds and methods of making
    发明人:BUYNAK JOHN D; RAO AKIREDDY SRINIVASA; DOPPALAPUDI VENKATA RAMANA
    权利人:UNIV SOUTHERN METHODIST
    摘要:Compounds of formula I: n nwherein R 1 , R 2 , R 3 , R 4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting β-lactamase enzymes, for enhancing the activity of β-lactam antibiotics, and for treating β-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.

    专利号:US-7429616-B2
    优先权日:2005-07-15
    标 题 :Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds
    发明人:BRABANDER JEF DE; JIANG XIN
    权利人:UNIV TEXAS
    摘要:The invention relates to the synthesis and complete stereochemical assignments of cytotoxic compounds such as compound 28-a and its stereoisomers: n nThe invention further provides processes for making the compounds, their synthetic intermediates, and for methods of using the compounds and their pharmaceutical compositions for the treatment of neoplastic diseases.

    专利号:US-5882901-A
    优先权日:1991-06-10
    标 题:Modified sialyl Lewisa compounds
    发明人:VENOT ANDRE P; NIKRAD PANDURANG V; KASHEM MOHAMMED A
    权利人:ALBERTA RES COUNCIL
    摘要:The present invention is drawn to methods for the synthesis of Lewis a derivatives modified at the C-2 and/or C-6 position of GlcNAc employing chemo-enzymatic synthesis. The derivatives find use in the treatment and prevention of diseases.
    武汉壹加壹生物科技有限公司
    小微企业
    注册号: 91420115MACCW9789M法定代表人:刘明
    注册资本:100万元人民币类型:有限责任公司(自然人投资或控股)
    成立日期:2023-3-17登记机关:武汉市江夏区市场监督管理局
    注册地址: 湖北省武汉市江夏区经济开发区大桥新区邢远长工业园4#楼2楼203
    一般项目:技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广,医学研究和试验发展,生物化工产品技术研发,化工产品销售(不含许可类化工产品),专用化学产品销售(不含危险化学品),合成材料销售,新型催化材料及助剂销售,实验分析仪器销售,技术玻璃制品销售,互联网销售(除销售需要许可的商品),货物进出口,技术进出口,日用百货销售,服装服饰零售,皮革制品销售,化妆品零售,文具用品零售,音响设备销售,五金产品零售,电子产品销售,新材料技术推广服务,新材料技术研发。(除许可业务外,可自主依法经营法律法规非禁止或限制的项目)
    免费会员现货
    http://www.yjybiochem.com
    企业联系电话:166 0273 9303👤
    📞 武汉壹加壹生物科技有限公司 联系方式
    联系人: 向玉田
    手机: 18995604068
    邮箱:673003916@qq.com
    微信 18995604068 | 2140408240
    QQ:2140408240
    ⚠️ 声明: 咨询或交易时请注意风险评估和信息核实,百琢研不参与任何交易。

    地址:湖北省武汉市江夏区经济开发区大桥新区邢远长工业园4#楼2楼203
    常规和库存产品100产品总量: 431
    武汉壹加壹生物科技有限公司logo
    平台资质认证✓营业执照✓
    CAS号:1415562-82-1
    中文名:(2R)-1-[[4-[[3-甲基-5-[(苯磺酰基)甲基]苯氧基]甲基]苯基]甲基]-2-吡咯烷甲醇
    英文名:PF-543
    纯度:99% HPLC1G/5G/1KG
    产品图片备注:现货
    主打产品,生产工厂、精细化学品、医药中间体、材料中间体
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Yi X, Tang X, Li T, Chen L, He H, Wu X, Xiang C, Cao M, Wang Z, Wang Y, Wang Y, Huang X. Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543. Biomed Pharmacother. 2023 Jul;163:114401. doi: 10.1016/j.biopha.2023.114401. Epub 2023 May 9. 11(2):e0276622. doi: 10.1128/spectrum.02766-22. Epub ahead of print.
    3: Bonica J, Clarke CJ, Obeid LM, Luberto C, Hannun YA. Upregulation of sphingosine kinase 1 in response to doxorubicin generates an angiogenic response via stabilization of Snail. FASEB J. 2023 Mar;37(3):e22787. doi: 10.1096/fj.202201066R.
    4: Cong D, Yu Y, Meng Y, Qi X. Dexmedetomidine (Dex) exerts protective effects on rat neuronal cells injured by cerebral ischemia/reperfusion via regulating the Sphk1/S1P signaling pathway. J Stroke Cerebrovasc Dis. 2023 Jan;32(1):106896. doi: 10.1016/j.jstrokecerebrovasdis.2022.106896. Epub 2022 Nov 15. 23(21):12741. doi: 10.3390/ijms232112741.

    合成参考文献


    参考文献:10.1194/jlr.m049759
    摘要:Cingolani F, Casasampere M, Sanllehí P, Casas J, Bujons J, Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. Journal of Lipid Research. 2014 Aug;55(8):1711–20. doi: 10.1194/jlr.m049759.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知